Clinical Trial Update: Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid [Phase 2]

View source ↗

Summary

Phase 2 safety and immunogenicity study of tgAAC09 HIV vaccine using an AAV capsid has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• tgAAC09 (AAV-based HIV vaccine expressing Gag-PR-RT)

Snippet

Sponsor: International AIDS Vaccine Initiative | Conditions: Human Immunodeficiency Virus Infections, HIV Infections | Phase 2 | Status: COMPLETED